CN101875692A - 中国仓鼠凋亡相关基因 - Google Patents

中国仓鼠凋亡相关基因 Download PDF

Info

Publication number
CN101875692A
CN101875692A CN2010102090432A CN201010209043A CN101875692A CN 101875692 A CN101875692 A CN 101875692A CN 2010102090432 A CN2010102090432 A CN 2010102090432A CN 201010209043 A CN201010209043 A CN 201010209043A CN 101875692 A CN101875692 A CN 101875692A
Authority
CN
China
Prior art keywords
sequence
cell
cells
seq
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010102090432A
Other languages
English (en)
Chinese (zh)
Inventor
黄智宏
米兰达·G·S·亚普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science, Technology and Research
Original Assignee
Agency for Science, Technology and Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science, Technology and Research filed Critical Agency for Science, Technology and Research
Publication of CN101875692A publication Critical patent/CN101875692A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2010102090432A 2004-12-30 2005-12-28 中国仓鼠凋亡相关基因 Pending CN101875692A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64033304P 2004-12-30 2004-12-30
US60/640,333 2004-12-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800488118A Division CN101133156A (zh) 2004-12-30 2005-12-28 中国仓鼠凋亡相关基因

Publications (1)

Publication Number Publication Date
CN101875692A true CN101875692A (zh) 2010-11-03

Family

ID=36615341

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2010102090432A Pending CN101875692A (zh) 2004-12-30 2005-12-28 中国仓鼠凋亡相关基因
CN2010102090324A Pending CN101875957A (zh) 2004-12-30 2005-12-28 中国仓鼠凋亡相关基因
CNA2005800488118A Pending CN101133156A (zh) 2004-12-30 2005-12-28 中国仓鼠凋亡相关基因

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN2010102090324A Pending CN101875957A (zh) 2004-12-30 2005-12-28 中国仓鼠凋亡相关基因
CNA2005800488118A Pending CN101133156A (zh) 2004-12-30 2005-12-28 中国仓鼠凋亡相关基因

Country Status (9)

Country Link
US (5) US7846894B2 (enExample)
EP (6) EP1997890A1 (enExample)
JP (1) JP5089400B2 (enExample)
KR (1) KR20070082597A (enExample)
CN (3) CN101875692A (enExample)
AU (1) AU2005322686B2 (enExample)
IL (1) IL183361A0 (enExample)
SG (1) SG158841A1 (enExample)
WO (1) WO2006071200A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107630038A (zh) * 2017-09-15 2018-01-26 浙江大学 提高老年大鼠骨髓间充质干细胞移植后生存能力的方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013234046B2 (en) 2012-03-16 2017-09-07 University Health Network Methods and compositions for modulating Toso activity
EP2674495A1 (en) * 2012-06-14 2013-12-18 Sanofi CHO expression system
WO2014068048A1 (en) * 2012-11-05 2014-05-08 Celonic Ag Expression system
CA2917077A1 (en) 2013-07-03 2015-01-08 University Health Network Antibodies to toso
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2019180607A1 (en) * 2018-03-19 2019-09-26 Centre For Cellular And Molecular Platforms A vector, a host cell and a method thereof
CN108359632A (zh) * 2018-03-30 2018-08-03 吉林冠界生物技术有限公司 Mdck细胞系、复制病毒的方法及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6747138B1 (en) 1995-04-03 2004-06-08 Regents Of The University Of Michigan Methods and compositions for regulating Fas-associated apoptosis
EP0816497A3 (en) * 1996-06-26 1999-12-22 Smithkline Beecham Corporation Human requiem polypeptide for apoptosis
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
GB9625283D0 (en) * 1996-12-04 1997-01-22 Janssen Pharmaceutica Nv Vertebrate homologues of unc-53 protein of c.elegans or functional eqivalents thereof and cdna sequences coding for said homologue
US20040143111A1 (en) * 1997-04-17 2004-07-22 Incyte Corporation Novel apoptosis-associated protein
US6451759B1 (en) 1998-01-14 2002-09-17 The Regents Of The University Of California Noncleavable Fas ligand
AU3753099A (en) * 1998-04-21 1999-11-08 Trustees Of Boston University Novel genes and methods that modulate apoptosis
US6683168B1 (en) 1998-04-21 2004-01-27 Boston Medical Center Corporation Genes and methods that modulate apoptosis
US6015712A (en) * 1999-07-19 2000-01-18 Isis Pharmaceuticals Inc. Antisense modulation of FADD expression
US6586206B1 (en) * 1999-09-27 2003-07-01 Genentech, Inc. Methods for making recombinant proteins using apoptosis inhibitors
US7575860B2 (en) * 2000-03-07 2009-08-18 Evans David H DNA joining method
US20040023385A1 (en) * 2002-08-05 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of requiem expression
WO2004070025A2 (en) * 2003-02-05 2004-08-19 Juan Saus Novel goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders
CN1548054A (zh) * 2003-05-08 2004-11-24 陆爱丽 预防或治疗sars冠状病毒的药物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107630038A (zh) * 2017-09-15 2018-01-26 浙江大学 提高老年大鼠骨髓间充质干细胞移植后生存能力的方法

Also Published As

Publication number Publication date
CN101133156A (zh) 2008-02-27
EP2298888A1 (en) 2011-03-23
CN101875957A (zh) 2010-11-03
AU2005322686B2 (en) 2012-01-19
US20110318316A1 (en) 2011-12-29
EP1997890A1 (en) 2008-12-03
EP2298887A1 (en) 2011-03-23
US20110129927A1 (en) 2011-06-02
JP5089400B2 (ja) 2012-12-05
US20110318831A1 (en) 2011-12-29
IL183361A0 (en) 2007-09-20
US20110318317A1 (en) 2011-12-29
WO2006071200A2 (en) 2006-07-06
JP2008526200A (ja) 2008-07-24
US20080295190A1 (en) 2008-11-27
WO2006071200A3 (en) 2007-01-25
EP2298889A1 (en) 2011-03-23
SG158841A1 (en) 2010-02-26
KR20070082597A (ko) 2007-08-21
AU2005322686A1 (en) 2006-07-06
EP1831366A2 (en) 2007-09-12
EP2298890A1 (en) 2011-03-23
US7846894B2 (en) 2010-12-07

Similar Documents

Publication Publication Date Title
DK2692865T3 (en) Transponeringsmedieret identification of specific binding proteins, or functional
KR101629071B1 (ko) 다수의 면역조절자를 발현하는 조작된 세포 및 그 용도
CN101553506B (zh) Lingo结合分子及其制药用途
CA2464239C (en) Psma antibodies and protein multimers
AU666176B2 (en) Mammalian expression systems for HCV proteins
KR20210142678A (ko) 변형된 원형 폴리리보뉴클레오티드를 포함하는 조성물 및 그의 용도
CN109913425B (zh) 一种重组流感病毒拯救方法及其在肿瘤治疗中的应用
KR20220024647A (ko) 원형 폴리리보뉴클레오티드의 투여 방법
KR20100049084A (ko) 질병 진단을 위한 방법 및 조성물
US20240207318A1 (en) Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
CN101875957A (zh) 中国仓鼠凋亡相关基因
KR20240021906A (ko) 발현 벡터, 박테리아 서열-무함유 벡터, 및 이를 제조하고 사용하는 방법
WO1994022487A1 (en) Use of a col 1a1 mini-gene construct to inhibit collagen synthesis
CN108531458A (zh) 治疗肿瘤的基因工程自然杀伤细胞产品
CN100338219C (zh) 成视网膜细胞瘤蛋白的组织特异性表达
KR20210106124A (ko) 고효율 발현 벡터 및 이의 용도
CN110195103B (zh) 一种监测miRNA表达变化报告基因影像探针及其构建方法
CN101760475B (zh) 重组逆转录病毒载体
CN117881788A (zh) 表达载体、无细菌序列载体及其制备和使用方法
WO2026052952A1 (en) Compositions and methods of therapy
HK40111561A (en) Expression vectors, bacterial sequence-free vectors, and methods of making and using the same
KR102721254B1 (ko) 형질전환시킨 중국햄스터난소 세포를 활용하여 시시엔5 단백질을 제조하는 방법
KR101590174B1 (ko) 세포 생존능 측정용 ｃｂａ-프로모터 리포터 벡터 및 그에 의해 형질감염된 세포주
KR20240023100A (ko) 유전자 발현을 조절하기 위한 조성물 및 방법
CN117062619A (zh) 包含用于同时表达存在于细胞中的蛋白质和分泌至细胞外的蛋白质的双重表达载体的用于预防或治疗癌症的组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20101103